CARDIFF ONCOLOGY, INC. Accounts Receivable
CARDIFF ONCOLOGY, INC. (CRDF) had Accounts Receivable of $189.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-11
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $189.00K.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $191.00K.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $182.00K.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $254.00K.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2026-06-30 | $189.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $191.00K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $182.00K 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $254.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $526.00K 10-Q · filed 2025-07-29 | |
| 2025-03-31 | $405.00K 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $773.00K 10-K · filed 2026-02-24 | |
| 2024-09-30 | $618.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $451.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $393.00K 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $288.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | $198.00K 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $161.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $676.00K 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $771.00K 10-K · filed 2024-02-29 | |
| 2022-09-30 | $650.00K 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $551.00K 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $447.00K 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $535.00K 10-K · filed 2023-03-02 | |
| 2021-09-30 | $395.00K 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $308.00K 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $242.00K 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $320.00K 10-K · filed 2022-02-24 | $320.46K 10-K · filed 2021-02-25 |
| 2020-09-30 | $204.37K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $109.33K 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $106.43K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $203.48K 10-K · filed 2021-02-25 | |
| 2019-09-30 | $152.04K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $122.28K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $115.68K 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $167.75K 10-K · filed 2020-02-27 | |
| 2018-09-30 | $128.58K 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $124.08K 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $114.34K 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $77.09K 10-K · filed 2019-03-06 | |
| 2017-09-30 | $178.13K 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $157.44K 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $80.35K 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $100.46K 10-K · filed 2018-02-26 | |
| 2016-09-30 | $85.15K 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $158.54K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $61.94K 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $98.74K 10-K · filed 2017-03-15 | |
| 2015-09-30 | $66.97K 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $99.72K 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $59.39K 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $56.69K 10-K · filed 2016-03-10 | |
| 2014-09-30 | $62.37K 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $59.91K 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $129.30K 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $78.99K 10-K · filed 2015-03-12 | |
| 2013-09-30 | $69.57K 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $56.50K 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $58.06K 10-Q · filed 2013-05-14 | |
| 2012-12-31 | $168.38K 10-K · filed 2014-03-17 | |
| 2012-09-30 | $128.19K 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $106.03K 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $76.53K 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $99.14K 10-K · filed 2013-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |